ArticleJournal of cannabis research2023
Anticancer properties of cannabidiol and Δ
Article in Journal of cannabis research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 13 citations in OpenAlex.
- Cannabinoids in Cancer: Molecular Mechanisms of Tumor Cell Death and Translational Opportunities.Biomolecules · 2026Review
- Cannabigerol and Cannabichromene Induce Lung Cancer Cell Death and Apoptosis-Contribution of PPARα to Cannabigerol Effects.Antioxidants (Basel, Switzerland) · 2026Article
- Antitumor Activity of Cannabinoids and Their Interaction with Chemotherapy: A Systematic Review and Meta-Analysis of Preclinical Evidence.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Identification of Changes in the Transcriptome Profile of Human Hepatoma HepG2 Cells Exposed to Combined Sorafenib and Cannabis Treatment.International journal of molecular sciences · 2026Article
- Cannabidiol-induced cellular and matrix-associated responses in primary equine sarcoid cells.Journal of veterinary internal medicine · 2026Article
- Cannabis sativa phytochemicals in cancer therapy: molecular mechanisms and therapeutic potential.Frontiers in pharmacology · 2026Review
- New Cannabinoids and Chlorin-Type Metabolites from the Flowers ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Exploring the therapeutic potential of cannabinoids in cancer by modulating signaling pathways and addressing clinical challenges.Discover oncology · 2024Review
- Identification and Characterization of Cannabichromene's Major Metabolite Following Incubation with Human Liver Microsomes.Metabolites · 2024Article
- Does cannabis elevate cancer risk? : Evidence from Mendelian randomization.Wiener klinische Wochenschrift · 2024Article
- Cytotoxicity of natural and synthetic cannabinoids and their synergistic antiproliferative effects with cisplatin in human ovarian cancer cells.Frontiers in pharmacology · 2024Article
- Ferroptosis resistance in cancer cells: nanoparticles for combination therapy as a solution.Frontiers in pharmacology · 2024Review
- Cell death induction and intracellular vesicle formation in human colorectal cancer cells treated with ΔGenes & genomics · 2023Article
- In vitro evaluation of cell viability and expression profile of growth factors in mouse Sertoli cells exposed to Delta-9-tetrahydrocannabinol: a mechanistic insight into the cannabinoid-induced testicular toxicity.BMC pharmacology & toxicology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
introductionWith the legalization of cannabis in multiple jurisdictions throughout the world, a larger proportion of the population consumes cannabis. Several studies have demonstrated anti-tumor effects of components present in cannabis in different models. Unfortunately, little is known about the potential anti-tumoral effects of cannabinoids in bladder cancer and how cannabinoids could potentially synergize with chemotherapeutic agents. Our study aims to identify whether a combination of cannabinoids, like cannabidiol and Δ
methodsWe generated concentration curves with several drugs, including several cannabinoids, to identify the range at which they could exert anti-tumor effects in bladder cancer cell lines. We tested the cytotoxic effects of gemcitabine (up to 100 nM), cisplatin (up to 100 μM), and cannabinoids (up to 10 μM) in T24 and TCCSUP cells. We also evaluated the activation of the apoptotic cascade and whether cannabinoids have the ability to reduce invasion in T24 cells.
resultsCannabidiol, Δ DISCUSSION: Our results indicate that cannabinoids can reduce human bladder transitional cell carcinoma cell viability, and that they can potentially exert synergistic effects when combined with other agents. Our in vitro results will form the basis for future studies in vivo and in clinical trials for the development of new therapies that could be beneficial for the treatment of bladder cancer in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.